San Diego-based Viking Therapeutics marked alone as a significant competitor in the weight loss drug market in February just after revealing promising facts from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as in March the company unv